Skip to main content

Mussallem Michael A's Form 4 filing

Edwards Lifesciences Corp (EW) · filed Apr 17, 2023

Accession no.
0001225208-23-004844
Filed
Apr 17, 2023
Trade date
Apr 14, 2023
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.67M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mussallem Michael ACIK 0001204551Director, Officer (Chairman & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 14, 2023Common StockMOption exerciseAcquired+29,375$35.20+$1,034,00090,322.82Direct
Apr 14, 2023Common StockSSaleDisposed−3,816$84.61F2−$322,871.7686,506.82Direct
Apr 14, 2023Common StockGGiftDisposed−9,500$0.00$077,006.82Direct
Apr 14, 2023Common StockSSaleDisposed−16,059$84.10F3−$1,350,561.960,947.82Direct
Apr 14, 2023Common StockGGiftAcquired+9,500$0.00$03,607,422Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 14, 2023Common StockMOption exerciseDisposed−29,375$0.00$029,375Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $84.43 to $84.88 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $83.42 to $84.42 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Read the full filing on SEC EDGAR (opens in a new tab)